Figure 3: Expression of GPR155 in clinical samples, and the cumulative incidence of hematogenous recurrence in patients with Stage II/II GC.
From: GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer
(A) Significantly lower levels of GPR155 mRNA were detected in primary GC tissues compared with the corresponding noncancerous mucosal tissues. Patients with Stage IV GC with synchronous hematogenous metastasis had lower expression levels of GPR155 mRNA compared with those of patients without hematogenous metastasis. (B) The optimal cut-off value of GPR155 expression was determined at 0.0009. (C) The cumulative incidence of hematogenous recurrence was significantly higher in the low GPR155 group patients with Stage II/III GC. Abbreviations: Hem-rec; hematogenous recurrence, Hem; synchronous hematogenous metastasis.
